ASCO: Results of IMpower110 study
Abstract No : 9594
Abstract Type : Poster Session
Indication : Non-Small Cell Lung Cancer
Intervention : Atezolizumab (atezo) vs chemotherapy
Company : F. Hoffmann-La Roche, Ltd
Technology : Monoclonal antibody
QLQ-C30 and QLQ-LC13 completion rates were high at BL and most study visits. TTD of lung cancer-related symptoms was similar in both arms, indicating pts’ low BL symptom burden was maintained for a similar duration. Pts receiving atezo vs chemo sustained numerical improvements in physical function and no worsening in lung cancer-related symptoms.
Read More: https://www.delveinsight.com/asco-conference/article/NCT02409342
ASCO: Results from CARTITUDE-1
Abstract No : 8505
Abstract Type : Oral Abstract Session
Indication : Multiple Myeloma
Intervention : JNJ-4528
Company : Janssen Research & Development, LLC
Technology : CAR T Cell Therapy
JNJ-4528 treatment led to responses in all pts. These responses were early, deep, and durable at a low dose of CAR-T cells with 26/29 (90%) pts progression free at median 9-mo follow-up. CRS was manageable in most pts, supporting outpatient dosing.
View More: https://www.delveinsight.com/asco-conference/article/NCT03548207
ASCO: Results of IMvigor130
Abstract No : 5011
Abstract Type : Clinical science symposium
Indication : Urothelial Carcinoma
Intervention : Atezolizumab
Company : Roche
Technology : Monoclonal antibody
These results reinforce the potential predictive nature of biomarkers associated with response/resistance to atezo and highlight potentially distinct biology driving benefit with atezo and atezo + PBC. These findings suggest a possible biomarker-directed approach to 1L mUC tx that warrants mechanistic interrogation and prospective validation.
Read More: https://www.delveinsight.com/asco-conference/article/imvigor130
CheckMate-649 Results at ESMO 2020
Abstract No : Abstract: #LBA6
Indication : Gastric Cancer, Gastroesophageal junction cancer and Esophageal Cancer
Intervention : Nivolumab
Company : Bristol-Myers Squibb
Technology : PD-1/PD-L1 inhibitor
NIVO is the first PD-1 inhibitor to demonstrate superior OS and PFS in combination with chemo vs chemo alone in previously untreated pts with advanced GC/GEJC/EAC, with a manageable safety profile. NIVO + chemo represents a potential newstandard 1L treatment option for these pts.
Read More: https://www.delveinsight.com/esmo-conference-2020/article/checkmate-649-NCT02872116-esmo-2020
ADAURA trial results at ESMO
ADAURA is a randomized, double-blinded, global, placebo-controlled phase III trial in the adjuvant treatment of 682 patients with stage IB, II, IIIA EGFRm NSCLC resulting in the complete tumor resection and adjuvant chemotherapy as indicated. Patients were treated with Tagrisso 80mg once-daily oral tablets or placebo for three years or until disease recurrence.
Keynote -361 Trial: Fails to Meet Primary Endpoints
“Danube phase III with dual checkpoint blockade versus standard chemo fails to improve outcomes. Keynote 361 IO vs. Chemo also negative. Perhaps Javelin 100 is positive because it’s already selected patients who responded to chemo for the use of maintenance IO”
Read More: https://www.delveinsight.com/esmo-conference-2020/article/urothelial-carcinoma-esmo-2020